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Comparison of Carboplatin and Doxorubicin-Based Chemotherapy
Protocols in 470 Dogs after Amputation for Treatment of
Appendicular Osteosarcoma
L.E. Selmic, J.H. Burton, D.H. Thamm, S.J. Withrow, and S.E. Lana
Background: Many chemotherapy protocols have been reported for treatment of canine appendicular osteosarcoma
(OSA), but outcome comparisons in a single population are lacking.
Objective: To evaluate the effects of protocol and dose intensity (DI) on treatment outcomes for carboplatin and doxo-
rubicin-based chemotherapy protocols.
Animals: Four hundred and seventy dogs with appendicular OSA.
Methods: A retrospective cohort study was performed comprising consecutive dogs treated (1997–2012) with amputa-
tion followed by 1 of 5 chemotherapy protocols: carboplatin 300 mg/m2 IV q21d for 4 or 6 cycles (CARBO6), doxorubicin
30 mg/m2 IV q14d or q21d for 5 cycles, and alternating carboplatin 300 mg/m2 IV and doxorubicin 30 mg/m2 IV q21d for
3 cycles. Adverse events (AE) and DI were evaluated. Kaplan–Meier survival curves and Cox proportional hazards regres-
sion were used to compare disease-free interval (DFI) and survival time (ST) among protocols.
Results: The overall median DFI and ST were 291 days and 284 days, respectively. A lower proportion of dogs pre-
scribed CARBO6 experienced AEs compared to other protocols (48.4% versus 60.8–75.8%; P = .001). DI was not associ-
ated with development of metastases or death. After adjustment for baseline characteristics and prognostic factors, none
of the protocols provided a significant reduction in risk of development of metastases or death.
Conclusions and Clinical Importance: Although choice of protocol did not result in significant differences in DFI or ST,
the CARBO6 protocol resulted in a lower proportion of dogs experiencing AEs, which could be advantageous in maintain-
ing high quality of life during treatment. DI was not a prognostic indicator in this study.
Key words: Canine; Limb amputation; Oncology; Primary bone tumor.
Osteosarcoma (OSA) is a biologically aggressiveprimary bone tumor that has a very high rate of
microscopic metastases at diagnosis in dogs.1 Curative-
intent treatments combine methods of local control
such as limb amputation, limb-sparing surgery, or
radiation therapy, with chemotherapy for treatment of
microscopic metastases.2 Amputation is a common
and efficacious method of local control for appendicu-
lar OSA; the addition of chemotherapy postoperatively
has been shown to improve survival times (ST).3–7
Many different chemotherapy protocols have been
described resulting in a large range of median
ST (235–540 days, with 1 study reporting up to
840 days).4–18 Among these studies, single agent car-
boplatin protocols with 4 doses have been evaluated.
Occasionally, this protocol is extended to 6 doses, but
to date limited outcome information has been
reported.8,19,20 Our clinical impression of using a
6-dose single agent carboplatin protocol is that this
protocol is well tolerated in dogs and results in com-
paratively long DFI and ST. Many studies have evalu-
ated 1 chemotherapy protocol or compared the
protocol to amputation alone, making comparisons of
different chemotherapy protocols difficult given the
diversity of baseline characteristics and prognostic
factors among study populations.
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Abbreviations:
99mTc technetium 99 m
AE adverse event
ALP serum alkaline phosphatase
CARBO4 chemotherapy protocol with carboplatin 300 mg/m2
IV q21d for 4 doses
CARBO6 chemotherapy protocol with carboplatin 300 mg/m2
IV q21d for 6 doses
CARBODOX6 chemotherapy protocol with carboplatin 300 mg/m2
IV and doxorubicin 30 mg/m2 IV on an alternating
schedule q21d for 3 cycles
CBC complete blood count
CI confidence interval
DFI disease-free interval
DI dose intensity
DOX5.2 chemotherapy protocol with doxorubicin 30 mg/m2
IV q14d for 5 doses
DOX5.3 chemotherapy protocol with doxorubicin 30 mg/m2
IV q21d for 5 doses
GI gastrointestinal
HR hazard ratio
OSA osteosarcoma
ST survival time
TD treatment delay
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The choice of chemotherapy protocol may be based
on the perceived benefit versus risk of the available
protocols with consideration of reported efficacy, toxic-
ity, intensity of the protocol for the dog and owner,
and cost. Many studies evaluating chemotherapy for
OSA have reported efficacy, toxicity, and duration of
the protocol, with few reporting a measure of chemo-
therapy protocol intensity.4–18 Dose intensity (DI) is a
measure of the intensity of the chemotherapy protocol
and is defined as the quantity of drug administered to
a dog per week of treatment (mg/m2/wk).21 The DI of
chemotherapy protocols for canine appendicular OSA
has rarely been reported, and to the authors’ knowl-
edge, DI has not been investigated as a prognostic
factor in canine OSA.10 The importance of the DI of
neo adjuvant chemotherapy protocols for treatment of
human OSA is controversial, but has been associated
with outcome in some studies.22–26
The primary purpose of this study was to evaluate
the effects of protocol choice on treatment outcomes
(adverse effects [AE], disease-free interval [DFI], and
ST) for 5 different chemotherapy protocols. The sec-
ondary purpose was to assess DI as a prognostic fac-
tor in the treatment of canine appendicular OSA. We
hypothesized that 6 doses of single agent carboplatin
chemotherapy would result in significantly longer DFI
and ST compared to other protocols. We further
hypothesized that DI would be associated with DFI
and ST in dogs with appendicular OSA.
Materials and Methods
Case Selection and Medical Record Review
An electronic medical record search of an institutional primary
bone tumor registry was performed to identify dogs diagnosed
with appendicular OSA between January 1, 1997, and April 30,
2012 that received treatment consisting of limb amputation and 1
of 5 protocols of IV carboplatin or doxorubicin-based chemo-
therapy or both. For inclusion in this retrospective cohort study,
dogs must have had pre operative thoracic radiographs or
computed tomography and histopathologic confirmation of the
diagnosis. Furthermore, dogs must have been prescribed and
received at least 1 treatment of 1 of 5 chemotherapy protocols
postoperatively. Exclusion criteria were presence or suspicion of
metastases at any site before amputation or prior treatment of
appendicular OSA with radiation (palliative or curative-intent)
protocols, chemotherapy, or surgery.
A medical record review was performed to obtain information
about baseline characteristics including age and body weight at
diagnosis, breed, sex, and neuter status. Previously reported
prognostic factors were assessed including presence or absence of
proximal humeral OSA, and results of hematology and serum
biochemistry performed at presentation (serum alkaline phospha-
tase [ALP], lymphocyte and monocyte counts).27,28 If the dog
received pre operative whole body scintigraphy (with technetium
99 m [99mTc]), the results of the test were recorded. Treatment
information was obtained from the medical record including date
of amputation, chemotherapy protocol prescribed, dose and
agent(s) administered, and body weight at each treatment. Date
of administration of the last dose of chemotherapy, total number
of doses received, and whether or not the protocol was completed
or terminated prematurely were recorded. If a dog failed to com-
plete the prescribed chemotherapy protocol, the reason for
premature termination was determined whenever possible. If che-
motherapy treatments were delayed, the duration of the delay
and reason were recorded. For this study, a clinically relevant
treatment delay (TD) was defined as a delay in administration of
chemotherapy for ≥7 days beyond the planned date of chemo-
therapy administration. The planned date of administration of
the first dose of chemotherapy was 14 days after amputation.
After the first dose of chemotherapy, the planned date of chemo-
therapy administration was estimated based on the prescribed
interval (either 14 or 21 days depending on the protocol) from
the previous dose of chemotherapy. The reason for TD was cate-
gorized as because of surgical complications, owner reasons (eg,
schedule, travel, finances), toxicity, or for unknown or other
specified reasons. Complete blood counts (CBC) from 7 to
21 days after administration of each chemotherapy dose were
reviewed to determine, if hematologic AEs had occurred. The his-
tory given by the dog owner at each visit throughout the dura-
tion of the protocol allowed identification of gastrointestinal (GI)
AEs. If present, these were retrospectively graded based on the
Veterinary Co-operative Oncology Group – Common Terminol-
ogy Criteria for Adverse Events v1.1.29
Chemotherapy Protocols
Dogs receiving single agent carboplatin chemotherapy proto-
cols were prescribed 300 mg/m2 of carboplatin administered IV
q21d for either 4 (CARBO4) or 6 cycles (CARBO6). Dogs receiv-
ing single agent doxorubicin protocols were prescribed 30 mg/m2
of doxorubicin administered IV either q14d (DOX5.2) or q21d
(DOX5.3) for a total of 5 cycles. Dogs prescribed an alternating
carboplatin and doxorubicin protocol (CARBODOX6) were
started with either agent at a dosage of 300 mg/m2 IV of car-
boplatin or 30 mg/m2 IV of doxorubicin; 1 agent was given q21d
on an alternating schedule for 3 cycles (3 doses of each agent for
a total of 6 doses).
Before the first dose of doxorubicin, screening with echocardi-
ography was performed in some dogs at the clinician and owners’
discretion. After the first dose, CBCs generally were performed at
7 or 14 days or both depending on clinician preference and the
protocol prescribed. For all protocols, dogs had a CBC per-
formed at each visit before administration of chemotherapy and
a TD of variable length (dependent on clinician preference) was
instituted, if the absolute neutrophil count was <2,000/lL or if
the platelet count was <75,000/lL. If AEs occurred, dose reduc-
tions were performed at the clinicians’ discretion.
Dose Intensity Evaluation
The target DI was calculated for each protocol by division of
total amount of each drug planned to be administered in each
protocol by the planned duration of the protocol and expressed
as a total mg/m2/wk. The actual DI for each chemotherapy agent
for each individual dog was calculated by the Hryniuk method as
the total milligrams per body surface area of each drug received
in the protocol divided by the actual duration of the protocol in
weeks.21 This was calculated to account for any TDs or dose
reductions that occurred. The body surface area at each dose was
calculated using the standard equation (BSA = 10.1 9 BW2/3/
10,000). The duration of the protocol was defined as the time
between the first dose of chemotherapy and 2 weeks for DOX5.2
or 3 weeks after the last dose of chemotherapy in all other proto-
cols.21
To allow comparison of DI across protocols and for inclusion
in the statistic analysis, the fractional DI was calculated to yield
the summation DI for each protocol. The fractional DI was cal-
culated as the actual DI for each agent divided by the target DI.
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If the dog received the full single agent chemotherapy protocol
without any dose reduction or delay then the target fractional DI
would be 1. For the dogs receiving CARBODOX6, the fractional
DI was calculated for each agent separately as the actual DI of
that agent divided by the target DI of the single agent protocol
(100 mg/m2/wk for carboplatin and 10 mg/m2/wk for doxorubi-
cin) resulting in target fractional DI of 0.6 for carboplatin and
0.6 for doxorubicin. The summation DI was calculated for the
CARBODOX6 protocol as the sum of the fractional DI for the
agents; carboplatin and doxorubicin were weighted equally based
on approximately equivalent relative potencies of the single
agents.10,30 Summation DI of the single agent protocols is equiv-
alent to the fractional DI. The mean  standard deviation actual
DI and summation DI were calculated as summary statistics for
each protocol.
Follow-up
Thoracic radiography was commonly recommended on the
day of the last dose of chemotherapy or 1 month after this dose
for all chemotherapy protocols. For the protocols with 6 pre-
scribed doses (CARBO6 and CARBODOX6), thoracic radiogra-
phy often was recommended before the 3rd or 4th dose of the
protocol. Technectium-99 m bone scans and other diagnostics
tests were performed when indicated at clinician and client
discretion. Diagnostic test reports were reviewed for the date of
development of metastases or recurrence and site of first metasta-
sis. After development of metastases or recurrence, additional
treatments were used based on clinician and owner preference.
Outcome information was prospectively obtained by recheck vis-
its, telephone interview of the referring veterinarian and owner,
or both as part of data collection for the institutional primary
tumor registry. Information collected included the date of first
detection of metastases or local recurrence, the first site of metas-
tases detected, date of loss to follow-up, death or euthanasia,
and reason for death or euthanasia.
Statistic Analysis
Continuous data were assessed graphically for normality and
described using mean and standard deviation if normally distrib-
uted, or median and interquartile range if nonnormally distrib-
uted. Frequencies and percentages were used to describe
categoric data. Baseline characteristics at diagnosis were com-
pared between groups of prescribed chemotherapy protocols
using ANOVA for continuous variables and Chi-square test for
categoric variables. When the overall ANOVA F-test result was
statistically significant, Tukey’s honest significant difference
posthoc tests were applied to determine the presence of pairwise
differences.
Kaplan–Meier methodology was used to generate survival
curves and calculate median DFI and ST with 95% confidence
intervals (CI). The DFI was calculated as the number of days
from the date of amputation to the date of first detection of
metastases or local recurrence, and the ST was calculated as the
number of days from amputation to death attributable to any
cause. Dogs were censored in the DFI analysis, if they did not
have documented metastases at the time of last follow-up or the
time of death. Dogs were censored in the survival analysis, if they
were alive at last follow-up or were lost to follow-up. The end
point of death attributable to any cause was chosen over death
caused by disease because of the aggressive nature of this disease.
Many dogs will die of disease, but there is potential for underrec-
ognition of death caused by disease because few may undergo
necropsy and some may not have imaging before euthanasia and
death. This in turn can result in longer STs than if death
attributable to any cause is considered. The authors elected to
utilize death attributable to any cause for this report so that the
estimates of survival would be more conservative.
Cox proportional hazards regression analysis was used to
evaluate associations between baseline characteristics (canine age
and body weight at diagnosis, breed [purebred versus mixed]),
previously identified prognostic factors (proximal humeral tumor
site, ALP, monocyte, and lymphocyte counts), chemotherapy
treatment factors (protocol, grade 3 or 4 toxicity, number of
TDs, or ≥2 TDs), and outcome measures (DFI and ST). Multi-
variable analysis was performed with Cox proportional hazards
regression analysis to allow adjustment for other variables to
assess protocol effectiveness on DFI and ST. Modified intent-to-
treat and per-protocol analyses were performed and reported to
assess chemotherapy protocol effectiveness. The modified intent-
to-treat analysis included all dogs prescribed the chemotherapy
protocol regardless of the number of doses administered to
allow assessment of treatment outcomes in both dogs that com-
pleted and those that did not complete the chemotherapy proto-
col to decrease the bias of exclusion of dogs experiencing rapid
disease progression. The per-protocol analysis included only
dogs that completed the prescribed chemotherapy protocol.
Given the susceptibility of this analysis to bias, the results from
the per-protocol analysis are presented in the supporting infor-
mation.
A power analysis was performed with the PASS software
packagea using a Cox proportional hazards model for compari-
sons of end points of DFI and ST among multiple groups
according to methods described by Lachin and Foulkes.31,32
Power calculations were performed to detect a hazard ratio of
0.75 (in 1 group) for 2 comparisons: a comparison of dogs receiv-
ing carboplatin (CARBO4 and CARBO6 [n = 200]) versus doxo-
rubicin (DOX5.2 and DOX5.3 [n = 200]) single agent protocols
and comparison of the 5 individual protocols (n = 100 in each
group). The power for comparison of the single agent protocols
was 0.73 and for the 5 protocols was 0.43.
Statistic significance was set at a = 0.05 and the statistic analy-
sis was performed using software packages SASb and GraphPad
Prism.c
Results
Patient Eligibility and Baseline Characteristics
Four hundred and ninety-nine dogs were examined
for eligibility after the medical record search; all dogs
received treatment with amputation and were pre-
scribed 1 of the 5 chemotherapy protocols described
for treatment of appendicular OSA. Twenty-nine dogs
were excluded after medical record review: 18 for doc-
umented presence of metastatic disease (12 lymph
node, 2 lung, and 4 bone), 8 for prior treatment with
palliative radiation, 2 for prior treatment with chemo-
therapy, and 1 dog failed to receive any doses of che-
motherapy after prescription of the protocol. Four
hundred and seventy dogs were confirmed eligible and
included in the statistic analysis. The baseline charac-
teristics of these dogs are described in Table 1. Of the
470 dogs, pre operative whole body scintigraphy (with
99mTc) was performed in the majority of dogs (317,
68.5%). After surgery, CARBO4 and CARBO6 proto-
cols were prescribed for 93 and 91 dogs, respectively,
CARBODOX6 was prescribed for 97 dogs, and
DOX5.2 and DOX5.3 were prescribed for 124 and 65
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dogs, respectively. These dogs formed the basis of the
modified intent-to-treat analysis presented. The tempo-
ral distribution of the prescription of the different pro-
tocols for these dogs (Fig 1) showed prescription of
DOX5.2 and DOX5.3 protocols in the early- to mid-
study period (1997–2005) whereas CARBODOX6 was
prescribed throughout most of the study period (1999–
2009). CARBO4 protocol was prescribed during the
mid- to late-study period (2002–2012) and CARBO6
was prescribed more commonly in the late-study per-
iod (2008–2012). Only 84 dogs (of 286 dogs; 29.4%)
had echocardiography performed before receiving
doxorubicin in the CARBODOX6, DOX5.2, and
DOX5.3 protocols. The only difference in baseline
characteristics among protocols was that dogs pre-
scribed CARBO6 had a significantly lower mean body
weight at diagnosis compared to dogs prescribed
CARBO4, CARBODOX6, and DOX5.2 (35.2 kg
versus 40.8 kg, 39.7 kg, and 39.7 kg, respectively;
P < .005), but not compared to DOX5.3 (38.3 kg;
P = .10).
Chemotherapy Protocols and DI
More than 50% of dogs completed the prescribed
chemotherapy protocols for all groups except
CARBO6 in which only 45.1% of dogs completed the
protocol (Table 2). The most common reason for early
termination of the chemotherapy protocol was devel-
opment of metastases in all protocols except CARBO6
in which owner reasons were the most common reason
for termination (25.3% of CARBO6 dogs; Table 2).
Inadequate finances and scheduling conflicts were
examples of owner reasons for delay. The mean dura-
tion of chemotherapy was 9 days longer in dogs com-
pleting the CARBO6 protocol compared to those
completing the CARBODOX6 protocol (138 versus
129 days). Comparing DI across protocols, the mean
summation DI was closest to the target summation DI
in dogs prescribed CARBO4 and DOX5.3 protocols
(0.9 versus 1; Table 2).
Treatment Outcome
A total of 295 dogs experienced AE; a lower propor-
tion of dogs prescribed CARBO6 experienced AE
compared to all other protocols (48.4% versus 62.3%
[CARBO4], 60.8% [CARBODOX6], 75.8% [DOX5.2],
and 61.5% [DOX5.3]; P = .001; Table 3). Grade 1 AE
were the most common highest-grade AE reported in
all protocols; the proportion of dogs experiencing
grade 3 and 4 AE was not significantly different
among protocols ranging from 4.1% to 9.6% (P = .62;
Table 3). Gastrointestinal AE comprised the majority
of all AE experienced in all protocols aside from
CARBO6 where hematologic AE was the most com-
mon (P < .0001; Fig 2). More AE were reported after
the first dose of chemotherapy in all protocols aside
from CARBO6, and the number of AE generally
tended to decrease as the number of administered
doses increased with all protocols (Fig S1). A greater
proportion of dogs (50.6%) had TD in the CARBO6
Table 1. Baseline characteristics of 470 dogs with
appendicular osteosarcoma.
Characteristic
Mean age,  SD (years) 8.6  2.5
Mean body weight,  SD (kg) 38.9  11.6
Sex and neuter status (%)
Female intact 7 (1.5)
Female spayed 209 (44.5)
Male castrated 239 (50.9)
Male intact 15 (3.2)
Breed (%)
Mixed 97 (20.6)
Purebred 373 (79.4)
Anatomic site (%)
Forelimb 295 (62.8)
Hindlimb 175 (37.2)
Proximal humeral tumor location 127 (27.0)
Median (IQR) blood work results at presentation
ALP (IU/dL) 92 (100)
Monocyte (9106 cells) 0.4 (0.4)
Lymphocyte (9106 cells) 1.3 (0.8)
SD, standard deviation; IQR, interquartile range; ALP, serum
alkaline phosphatase.
Fig 1. Temporal distribution of the prescribed chemotherapy protocols over the study period.
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treatment protocol compared to other protocols (30.8–
41.9%; Table S1). TD occurred throughout the chemo-
therapy protocols with no other consistent trends
occurring across or within the protocols (Fig S2).
Owner reasons and toxicity were the most common
reasons for TD in all protocols (Table S1). Reasons
for TD were considered unknown, if the medical
records failed to provide sufficient information to
determine the reason for delay.
The median DFI for all dogs prescribed any chemo-
therapy protocol (modified intent-to-treat analysis) was
291 days (95% CI: 253, 362 days) and the median ST
was 284 days (95% CI: 248, 316 days). One hundred
and seventy-six dogs did not have documented meta-
static disease at the time of last follow-up or death.
The distribution of metastatic disease, first site of
metastasis, and whether or not the dog received medi-
cal treatment for metastatic disease are summarized by
protocol in Table 4. Thirty-one dogs were alive and 13
dogs were lost to follow-up; these dogs were censored
in the survival analysis. The median follow-up time for
censored dogs was 1,439 days (95% CI: 1,252,
3,372 days). Survival at 1, 2, and 3 years is summa-
rized in Table 5.
Table 2. Summary of chemotherapy treatment and dose intensity (DI) information for 470 dogs with appendicu-
lar osteosarcoma.
CARBO4
(93 dogs)
CARBO6
(91 dogs)
CARBODOX6
(97 dogs)
DOX5.2
(124 dogs)
DOX5.3
(65 dogs)
Doses received, median (IQR) 4.0 (1.0) 5.0 (2.0) 6.0 (2.0) 5.0 (0) 5.0 (1.0)
Completion of protocol, dogs (%) 57 (61.3) 41 (45.1) 59 (60.8) 97 (78.2) 37 (56.9)
Duration of chemotherapy (days), mean (SD)
All dogs 79 (29) 111 ( 39) 112 (33) 73 (46) 92 (32)
Dog that completed protocol 92 (11) 138 (17) 129 (13) 75 (39) 112 (18)
Reasons for early termination (%)
Metastases 22 (23.7) 20 (22.0) 16 (16.5) 18 (14.5) 18 (27.7)
Owner reasons 8 (8.6) 23 (25.3) 8 (8.3) 0 (0.0) 5 (7.7)
Death attributable to any cause 1 (1.1) 0 (0.0) 1 (1.0) 5 (4.0) 1 (1.5)
Toxicity 1 (1.1) 0 (0.0) 3 (3.3) 2 (1.6) 2 (3.1)
Other 0 1a (1.1) 2b (2.2) 1c (1.6) 2d (3.1)
Unknown 3 (3.2) 1 (1.1) 4 (4.1) 0 (0.0) 1 (1.5)
Target DI, mg/m2/wk 100.0 100.0 60.0 15.0 10.0
Actual DI, mg/m2/wk, mean (SD) 85.3 (14.6) 84.7 (11.1) C:49.4 (13.9)
D:4.1 (1.3)
12.6 (2.7) 8.9 (1.2)
Target summation DI 1.0 1.0 1.2 1.0 1.0
Summation DI, mean (SD) 0.9 (0.1) 0.8 (0.1) 0.9 (0.1) 0.8 (0.2) 0.9 (0.1)
SD, standard deviation; IQR, interquartile range; C, carboplatin; D, doxorubicin.
aThe dog had a cervical myelopathy of unknown cause.
bOne dog had hindlimb mobility problems and 1 dog had recurrence at amputation site.
cOne dog had elbow luxation that had amputation of that limb.
dOne dog had poor HL mobility and 1 dog had worsening chronic renal disease.
Table 3. The highest-grade toxicity seen in 470 dogs with appendicular osteosarcoma treated with limb amputa-
tion and prescribed carboplatin and doxorubicin-based chemotherapy protocols.
Protocol
No Reported
Toxicity (%)
Grade (%)
1 2 3 4 5
CARBO4 35 (37.6) 37 (39.8) 17 (18.3) 1 (1.1) 3 (3.2) 0 (0.0)
CARBO6 47 (51.6) 29 (31.9) 9 (9.9) 3 (3.3) 3 (3.3) 0 (0.0)
CARBODOX6 38 (39.2) 37 (38.1) 13 (13.4) 4 (4.1) 4 (4.1) 1 (1.0)
DOX5.2 30 (24.2) 48 (38.7) 34 (27.4) 7 (5.6) 5 (4.0) 0 (0.0)
DOX5.3 25 (38.5) 20 (30.8) 16 (24.6) 4 (6.2) 0 (0.0) 0 (0.0)
Fig 2. Distribution of type of adverse events by chemotherapy
protocol.
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For dogs that completed the chemotherapy protocol
(per-protocol analysis) the median DFI was 398 days
(95% CI: 317, 492 days) and median ST was 367 days
(95% CI: 325, 401 days). One hundred and twenty-one
dogs had no documented metastases at the time of last
follow-up or death. Twenty-four dogs were censored in
the survival analysis (20 were alive at last follow-up
and 4 dogs were lost to follow-up). The median
follow-up of censored dogs was 3,372 days (95% CI:
1,256, 3,372 days).
Factors associated with DFI, ST, or both in the uni-
variable analysis included age at diagnosis, body
weight, purebred dog, proximal humeral tumor loca-
tion, ALP, lymphocyte count, TD, treatment after
development of metastatic disease, and summation DI
(Table 6 and Table S2). Insufficient information was
available for calculation of DI in 77 dogs. Summation
DI was associated with an increased hazard of metas-
tases or recurrence in all dogs (HR, 2.82; 1.05, 7.63;
P = .04), but was not prognostic for survival in all
dogs.
In the univariable analysis, dogs that received the
CARBO6 protocol had a significantly lower risk of
developing metastases (only dogs that completed the
protocol) and of death attributable to any cause (in all
dogs and dogs that completed the protocol) (Table 6
and Table S2). In the multivariable analysis after
adjustment for age at diagnosis, body weight, purebred
dog, proximal humeral tumor location, ALP, and
treatment after development of metastatic disease (ST
Table 4. Summary of distribution of first metastatic disease event and treatment for metastatic disease by chemo-
therapy protocol.
CARBO 4 CARBO6 CARBODOX6 DOX5.2 DOX5.3
Number of dogs that developed metastases 63 (67.7%) 48 (52.8%) 66 (68.0%) 81 (65.3%) 36 (55.4%)
First site of mets/recurrence
Lungs 43 35 49 60 30
Bone 13 12 5 14 2
Lungs and bone 2 0 7 2 0
Recurrence 0 0 1 0 0
Othera 5 1 4 5 4
Treatment for metastasesb
IV chemo 9 3 2 1 0
Metronomicsc 7 8 7 0 7
IV chemo followed by metronomicsc 3 0 0 0 0
Toceranibd  metronomic cyclophosphamide 2 8 1 0 0
aOther organs including skin, lymph nodes, abdominal organs.
bOther than prednisolone or nonsteroidal anti-inflammatory alone.
cMetronomic cyclophosphamide and a nonsteroidal anti-inflammatory.
dPalladia, Zoetis, Florham Park, NJ.
Table 5. Proportion of dogs surviving at 1, 2, and
3 years after amputation and different adjuvant che-
motherapy protocols.
Prescribed
Chemotherapy
Protocol
1-year
Survival
Proportion
2-year
Survival
Proportion
3-year
Survival
Proportion
CARBO4 0.35 0.19 0.09
CARBO6 0.38 0.13 0.03
CARBODOX6 0.44 0.20 0.10
DOX5.2 0.42 0.15 0.04
DOX5.3 0.29 0.14 0.06
Table 6. Factors associated with disease-free interval (DFI), survival times, or both (ST) in univariable analysis
for the modified intent-to-treat analysis.
Variable
DFI ST
HR (95% CI) P value HR (95% CI) P value
Age at diagnosis (years) 0.99 (0.95, 1.04) .69 1.05 (1.01, 1.09) .02
Body weight (kg) 1.02 (1.01, 1.03) <.001 1.02 (1.01, 1.03) <.001
Pure breed dog 1.40 (1.04, 1.87) .027 1.35 (1.06, 1.72) .016
Proximal humeral tumor 1.50 (1.16, 1.93) .0017 1.49 (1.20, 1.85) <.001
ALP (continuous) 1.001 (1.000, 1.001) .0084 1.000 (1.000, 1.001) .048
Lymphocyte count (continuous) 0.82 (0.66, 1.02) .074 0.78 (0.65, 0.93) .006
Treatment delays (continuous) 0.85 (0.76, 0.96) .007 0.92 (0.83, 1.00) .06
Summation dose intensity 2.82 (1.05, 7.63) .04 1.84 (0.82, 4.14) .14
Treatment following development
of metastatic disease
– – 1.89 (1.41, 2.54) <.0001
HR, hazard ratio.
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only), the risks of development of metastases and
death attributable to any cause were not significantly
associated with protocol choice (Table 7 and Table S3;
Fig S5 and S6). The results were not adjusted for all
baseline, prognostic, and chemotherapy factors
because of concerns about collinearity. There was no
difference in risk of development of metastases and
death attributable to any cause between dogs receiving
carboplatin single agent protocols (CARBO4 and
CARBO6) versus doxorubicin single agent protocols
(DOX5.2 and DOX5.3) (Table 7 and Table S3).
Discussion
The lowest risk of development of metastases and
death attributable to any cause was seen in dogs pre-
scribed or having completed the CARBO6 protocol,
but after adjustment for baseline characteristics and
prognostic factors, the result was not statistically sig-
nificant. This protocol also resulted in the lowest pro-
portion of dogs experiencing toxicity of any protocol.
The study population baseline characteristics and
treatment outcomes reported were similar to previous
reports.4–18 Dogs prescribed CARBO6 had lower mean
body weight than dogs prescribed other protocols. In
this cohort and in other reports, body weight was
identified as a prognostic factor, with heavier dogs
having worse treatment outcomes.8,33 This in part may
explain changes in risk and lack of statistic significance
for the CARBO6 protocol after adjustment for this
and other factors in the multivariable Cox regression
analysis. Another theoretical reason for longer survival
in this group could be differences in treatment of meta-
static disease with more dogs prescribed CARBO6
receiving toceranib,d which may have resulted in delay
of progression of metastatic disease and prolongation
of survival.34 However, this was not the case in this
study with increased hazard of death resulting in dogs
that received treatment after development of metastatic
disease. This finding could be because of selection bias
resulting in owners or veterinarians being more likely
to pursue or recommend treatment for metastatic dis-
ease in more biologically aggressive cases. The lack of
detected difference among protocols could be a result
of a lack of true difference between the evaluated pro-
tocols with the majority of the evaluated protocols
being single agent protocols differing in agent, number
of doses, or DI. In people, multi agent protocols are
favored for treatment of OSA and are associated with
5-year survival of >60%. A recent evaluation of a car-
boplatin and doxorubicin protocol in a developing
country reported poorer survival outcomes in human
patients.35,36 Alternatively, it is possible that a differ-
ence existed, but was not detected because of the pro-
tocol group sample size resulting in relatively low
power and higher risk of type 2 error.
Decreased toxicity was identified in dogs prescribed
CARBO6, with the majority of the toxicity being he-
matologic rather than GI as in the other protocols. A
smaller proportion of dogs may have experienced AE
with this protocol because of lower DI of the protocol,
meaning dogs were receiving lower doses weekly
because of dose reductions or TD. This hypothesis is
supported by a lower summation DI of 0.8 compared
to the target summation DI of 1 for this protocol. In
addition, the apparent lower toxicity could be the
result of reporting. Adverse events may not have been
reported by owners or healthcare professionals inter-
viewing owners especially after the last doses of longer
protocols because of habituation to milder GI AE.
This could explain why the CARBO6 protocol had
apparently lower toxicity than the CARBO4 protocol.
Given that the majority of the AE in the CARBO6
group were hematologic, events may have been under-
appreciated because although CBCs were taken imme-
diately before each dose, after the first dose interim
CBCs may not have been performed unless toxicity
was detected. Furthermore, there may be increased
individual canine variation in timing of the neutrophil
and platelet nadirs with carboplatin compared to
doxorubicin. There also could be differences among
dogs receiving multiple cycles of treatment with some
Table 7. The effect of chemotherapy protocol on disease-free interval (DFI) and survival times (STs) for the
modified intent-to-treat analysis.
Protocols
DFI ST
Median DFI
(days)
Crude
HR
Adjusteda
HR (95% CI) P value
MST
(days)
Crude
HR
Adjustedb
HR (95% CI) P value
CARBO4 282 1.02 1.13 (0.79, 1.60) .50 299 0.88 0.83 (0.61, 1.13) .23
CARBO6 399 0.74 0.83 (0.57, 1.20) .32 306 0.72c 0.75 (0.54, 1.03) .08
CARBODOX6 302 0.93 0.99 (0.70, 1.40) .97 314 0.80 0.85 (0.63, 1.13) .26
DOX5.2 269 1.0 1.0 (ref) – 252 1.0 1.0 (ref) –
DOX5.3 302 0.90 1.08 (0.73, 1.62) .69 241 0.91 1.00 (0.72, 1.39) .99
Carboplatin 298 0.91 0.95 (0.73, 1.25) .72 301 0.84 0.89 (0.71, 1.12) .31
Doxorubicin 276 1.0 1.0 (ref) – 248 1.0 1.0 (ref) –
aAdjusted for age at diagnosis, body weight, purebred dog, proximal humeral tumor location, and ALP.
bAdjusted for age at diagnosis, body weight, purebred dog, proximal humeral tumor location, ALP, and treatment after development
of metastatic disease.
cSignificant decrease in hazard ratio (HR) in the univariable analysis. Carboplatin, single agent carboplatin protocols (CARBO4
CARBO6); doxorubicin, single agent doxorubicin protocols (DOX5.2, DOX5.3).
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dogs showing apparent worsening of nadirs with sub-
sequent doses because of individual variation in bone
marrow recovery time among individual dogs receiving
carboplatin and doxorubicin. The use of different an-
tiemetics (eg, maropitante) during the study period also
could have affected the rates of GI AE. The use of
drugs to decrease AE was not recorded in this study,
making it difficult to estimate the effect this had on the
frequency of AE.
High summation DI was associated with an
increased hazard of development of metastases and
was not associated with survival in this study. This
finding conflicted with the strong associations that
have been identified between increased DI of metho-
trexate and doxorubicin and survival in humans with
OSA.23,25 To date, the effect of the DI of carboplatin
on survival in humans with OSA is unknown. The
observed effect of DI on DFI may have been affected
by factors influencing DI including TD. TD in this
study often were because of owner reasons rather than
toxicity, which may have resulted in lower actual and
summation DI. Alternatively, the association between
summation DI and DFI could have resulted from type
1 error. This study does not provide evidence to sug-
gest that decreasing DI will result in the same or
improved survival, nor does it support recommenda-
tion of further dose intensification of existing
protocols.
The CARBO6 protocol had the highest proportion
of dogs experiencing TD and the lowest proportion
of dogs that completed the protocol, with dogs more
commonly being withdrawn for owner reasons rather
than development of metastases. The high proportion
of dogs experiencing TD could have been related to
the greater proportion of hematologic AE experienced
by dogs prescribed this protocol, resulting in a
greater likelihood of TD compared to dogs experienc-
ing GI signs. This conclusion is supported by the rel-
atively high proportion of TD reported because of
toxicity in dogs prescribed CARBO6 (30.4%). The
most likely reason for low protocol completion could
be that the owners were more likely to consider stop-
ping after 4 doses of carboplatin given it was an
established protocol and that staging at mid point of
the protocol could have led to increased probability
of detection of metastases and termination before
completion.
The study population was assessed for prognostic
factors, and common prognostic factors reported in
other studies also were found in this study including
body weight, proximal humeral tumor location, and
ALP.8,27,33 Because of the observational nature of this
study and lack of randomization, it was necessary to
adjust for these factors across groups in the Cox pro-
portional hazards regression analysis to assess the
effect of chemotherapy protocol on DFI and ST. A
limitation of this approach is that adjustment can only
be performed for measured factors. Other unmeasured
factors that could influence the treatment effect may
have been present, but were not considered. Other
study limitations include that re-evaluation thoracic
radiographs were recommended every 2–3 months, but
were performed at the discretion of the owner. This
may have resulted in lengthening of DFI caused by
increased censorship, if radiographs were not taken
and development of metastasis could not be docu-
mented or because of less frequent radiographs being
performed resulting in detection of metastases at a
later time point. Routine staging with whole body scin-
tigraphy after amputation was not performed in dogs
in this cohort, making it difficult to assess the effect of
occult bone metastases on outcome in this study.
Given the nonuniform collection of postchemotherapy
CBC (7–21 days posttreatment), there may have been
differences in the distribution of hematologic AE
because of less appreciation of AE in individual dogs
or relative under- or over appreciation of hematologic
AE in some protocols because of different monitoring
recommendations by clinicians and variable owner
compliance. Some dogs did not have full data available
for each chemotherapy dose (body weight, drug dose,
date of chemotherapy) to allow calculation of DI,
which resulted in a smaller dataset to evaluate summa-
tion DI as a prognostic factor. These dogs often
received at least 1 chemotherapy dose at their local
veterinarian often because of owner convenience and
consequently were assumed to be missing at random
(not introducing bias) but having the effect of decreas-
ing available sample size, which could have decreased
power and resulted increased probability of type 2
error.
Although choice of carboplatin- or doxorubicin-
based chemotherapy protocol did not result in signifi-
cant differences in DFI or ST in this study, the
CARBO6 protocol resulted in a lower proportion of
dogs experiencing AE, which could be an advantage in
maintaining high quality of life in dogs during treat-
ment for appendicular OSA. DI was not a prognostic
indicator for dogs treated with amputation and
adjuvant chemotherapy in this study.
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